Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage immuno-oncology company at the forefront of advancing cancer treatment methodologies. The company specializes in the development and commercialization of innovative, stem cell-based platforms designed to enhance the delivery and effectiveness of oncolytic viruses in cancer therapy.
Calidi’s core business involves leveraging its proprietary Neuro-Cells™ and SuperNova™ technology platforms. These platforms are engineered to deliver oncolytic viruses directly to tumor sites, ensuring targeted and potent cancer cell destruction while minimizing damage to surrounding healthy tissues.
Among the company's recent achievements, Calidi has successfully completed several preclinical studies demonstrating the efficacy and safety of its therapeutic candidates. Currently, Calidi is undergoing multiple Phase I/II clinical trials to further validate these findings and advance towards regulatory approvals.
Financially, Calidi Biotherapeutics has secured significant investment and formed strategic partnerships with key players in the biotechnology and pharmaceutical industries. These collaborations aim to accelerate the development timelines and expand the potential applications of their oncolytic virus therapies.
Calidi’s commitment to innovation and excellence is evident in its robust pipeline of products and ongoing research initiatives. The company continues to explore new avenues for the application of its technologies, with the ultimate goal of offering effective and life-saving treatments for cancer patients worldwide.
For the latest updates and news about Calidi Biotherapeutics, including their ongoing clinical trials and partnerships, visit their official news section.
Calidi Biotherapeutics (NYSE: CLDI) reported Q3 2024 financial results and key developments. The FDA cleared Northwestern University's IND application for NeuroNova (CLD-101), with Phase 1b/2 clinical trials in high-grade glioma expected to begin in early 2025. The company presented data on RTNova (CLD-400), their systemic antitumor virotherapy platform, at multiple conferences. Financially, Calidi reported a net loss of $5.1 million ($0.65 per share) compared to $2.0 million ($1.41 per share) in Q3 2023. The company raised $2 million through a registered direct offering and had $1.9 million in cash as of September 30, 2024.
Nexalin Technology (Nasdaq:NXL) and Calidi Biotherapeutics will be featured on Bloomberg TV's RedChip Small Stocks, Big Money show on October 26, 2024, at 7 p.m. ET. Nexalin's CEO Mark White will discuss their non-invasive neurostimulation technology for mental health treatment, including the Gen-3 HALO Clarity device, targeting a market projected to reach $537 billion by 2030. The technology addresses conditions like insomnia, PTSD, and traumatic brain injuries. Calidi's Chief Business Officer Stephen Thesing will present their oncolytic virotherapy developments for cancer treatment, featuring both systemic and localized approaches with engineered viruses protected by cell-based technologies.
Calidi Biotherapeutics (NYSE: CLDI) announces upcoming presentations of data supporting RTNova, their systemic antitumor virotherapy platform, at three major scientific conferences. The presentations will take place at the International Oncolytic Virotherapy Conference in Rotterdam (Oct 27-30), Immuno US 2024 in San Diego (Oct 28-30), and the Society for Immunotherapy of Cancer Annual Meeting in Houston (Nov 6-10).
RTNova is designed to target multiple tumor sites while evading the humoral immune system, offering potential treatment for previously untreatable metastatic diseases. The platform works by killing tumor cells and modifying the tumor immune microenvironment. Dr. Antonio Santidrian and Dr. Duong Nguyen will lead the presentations, sharing insights on this innovative therapeutic approach.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced a $2 million registered direct offering and concurrent private placement. The company will sell 2,050,000 common stock shares at $1.00 per share, along with series E and F warrants to purchase up to 2,050,000 shares each at $1.13 per share. Series E warrants have a one-year term while Series F warrants extend to five years, both exercisable after six months. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. The proceeds will support working capital, general corporate purposes, and pre-clinical and clinical trials. The closing is expected around October 24, 2024.
Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced that NYSE Regulation staff has decided to initiate delisting proceedings for the company's warrants (ticker symbol CLDI WS) from the NYSE American. The warrants, each exercisable for 1/10th of a common stock share at $115.00 per whole share, will be suspended from trading immediately.
The delisting decision is based on Section 1001 of the NYSE American Company Guide, citing the warrants' low trading price as unsuitable for listing. Calidi's common stock (CLDI) will continue to trade on the NYSE American. The company has the right to appeal this decision to the Listings Qualifications Panel. Upon completion of all procedures, including any potential appeal, the NYSE American will apply to the SEC for the official delisting of Calidi's warrants.
RedChip Companies will air interviews with Calidi Biotherapeutics (NYSE American:CLDI) and Gorilla Technology Group (Nasdaq:GRRR) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV on October 19 at 7 p.m. ET. The show reaches an estimated 73 million homes across the U.S.
Calidi Biotherapeutics is pioneering oncolytic virotherapy (OV) for cancer treatment. Their approach uses engineered viruses to target cancer cells and stimulate immune response. Calidi's cell-based technologies protect OVs from immune system elimination, potentially increasing efficacy.
Gorilla Technology, with 22 years of experience and 29 global patents, specializes in digital transformation solutions. Their technologies include edge AI, big data analytics, and IoT security, serving sectors like government and manufacturing. Gorilla has buy ratings from three analysts with a mean price target of $29.50.
Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of Northwestern University's IND application for CLD-101, a novel stem-cell based platform delivering oncolytic viruses to tumors. A Phase 1b/2 clinical trial for newly diagnosed high-grade glioma is expected to start in late 2024 at Northwestern University. The trial will evaluate safety and feasibility of multiple CLD-101 doses in addition to standard treatments.
A previous Phase 1 study at Northwestern showed promising results, with median progression-free survival of 9.05 months and overall survival of 18.4 months. CLD-101 is also being evaluated in a Phase 1 trial for recurrent high-grade glioma at City of Hope, with interim data expected in the first half of 2025. City of Hope received a $5.3 million grant from CIRM to support CLD-101 studies in ovarian cancer.
Calidi Biotherapeutics Inc. (NYSEAM: CLDI) reported its Q2 2024 financial results and recent business highlights. Key developments include:
1. Launched Nova Cell subsidiary with a $2 million investment from Dr. Ronald Rigor to advance AAA stem cell programs.
2. Strengthened team with appointments of Dr. George E. Peoples to the Board of Directors and Dr. Mark Gilbert to the Medical Advisory Board.
3. Received a new U.S. patent for SuperNova technology, enhancing the CLD-201 program.
4. Reported a net loss of $5.8 million ($1.40 per share) for Q2 2024, compared to $12.5 million ($14.24 per share) in Q2 2023.
5. R&D expenses were $2.2 million, down from $3.2 million in Q2 2023.
6. Cash position of $0.8 million as of June 30, 2024.
RedChip Companies will air interviews with GreenPower Motor Company Inc. (Nasdaq:GP) and Calidi Biotherapeutics, Inc. on Bloomberg TV on August 3, 2024, at 7 p.m. ET. Fraser Atkinson, CEO of GreenPower, will provide a corporate update on the show. GreenPower is a leading manufacturer of all-electric, zero-emission medium and heavy-duty vehicles for various sectors including cargo, delivery, shuttle, transit, and school buses.
The company has delivered over 700 vehicles to date and maintains a significant order book. GreenPower's competitive positioning, sales growth, and market dynamics highlight its potential for sustained growth in the EV industry. The interview will be accessible online through a provided link.
Calidi Biotherapeutics (NYSE American: CLDI) has launched a new subsidiary, Nova Cell, Inc., and secured a $3 million investment from Dr. Ronald Rigor. The investment includes $2 million for Nova Cell and $1 million for Calidi's oncology pipeline. Nova Cell will focus on advancing Calidi's Adult Adipose Allogeneic (AAA) stem cell programs for regenerative medicine applications.
Dr. Rigor, a Board-Certified Dermatologist and Stem Cell Therapy expert, joins Calidi's Scientific and Medical Advisory Board. He receives exclusive rights to use AAA stem cells and Calidi's CLD-201 product in the Philippines. Nova Cell aims to tap into the global stem cell therapy market, projected to reach $31.4 billion by 2030. The company plans to begin generating revenue by supplying AAA stem cells to Dr. Rigor's patients in 2025.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
What is Calidi Biotherapeutics, Inc.?
What technologies does Calidi Biotherapeutics use?
What is the current focus of Calidi Biotherapeutics?
Has Calidi Biotherapeutics achieved any recent milestones?
Who are Calidi Biotherapeutics' industry partners?
What is the goal of Calidi’s stem cell-based platforms?
What are oncolytic viruses?
Where can I find the latest news about Calidi Biotherapeutics?
What are the main products of Calidi Biotherapeutics?
What is the long-term vision of Calidi Biotherapeutics?
